Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL).
Yucai Wang(Mayo Clinic), Wei Ding(Ministry of Education of the People's Republic of China), Sameer A. Parikh(Mayo Clinic), Casey N. Aitken(Mayo Clinic in Arizona), Thomas M. Habermann(Mayo Clinic in Arizona), Tait D. Shanafelt(Mayo Clinic), Paul J. Hampel(Mayo Clinic), Betsy LaPlant(Mayo Clinic), Timothy G. Call(Mayo Clinic in Arizona), Ivana N. Micallef(Mayo Clinic), Saad S. Kenderian(Mayo Clinic in Arizona), Amber B. Koehler(Mayo Clinic in Arizona), Stephen M. Ansell(Mayo Clinic), Grzegorz S. Nowakowski(Université Claude Bernard Lyon 1), Eli Muchtar(Mayo Clinic), Rong He(Mayo Clinic), Sutapa Sinha(WinnMed), Neil E. Kay(Mayo Clinic), José F. Leis(Mayo Clinic), Thomas E. Witzig(WinnMed)
Cited by 9
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Executive Leadership and Physician Well-being
|Mayo Clinic Proceedings|2016|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k